H 2 S Production in the Diabetic Kidney
In the last two decades, H 2 S has overcome its past reputation as a toxic gas and gained attention as a molecule involved in several biological functions. H 2 S was initially described as a neuromodulator by Abe and Kimura in 1996 (1) . In the last decade, other studies have described its role in vasorelaxation (48) , angiogenesis (4) , nociception (28, 42) , cytoprotection (15, 40) , myocardial ischemia-reperfusion injury (7), atherosclerosis (5), including diabetic complications (25, 29) . Endogenously, H 2 S is generated by cystathionine ␤-synthase (CBS), cystathionine ␥-lyase (CSE), 3-mercaptopyruvate sulfurtransferase (3MST) together with cysteine amino transferase (CAT), and D-amino acid oxidase (DAO) in concert with 3MST (1, 10, 37, 38) . A detailed pathway of H 2 S synthesis has recently been reviewed by Beltowski (3) .
Although the distribution of H 2 S-producing enzymes is tissue specific, the kidney is known to express CBS and CSE (14) . In diabetes, the level and activity of both these enzymes are reported to be impaired, and thus H 2 S production leads to endothelial and other cell type injury (18, 21, 44) . A lower plasma H 2 S concentration in DN patients on hemodialysis was shown to correlate with the progression of atherosclerosis (23) . Other researchers including our own study showed that H 2 S production in the diabetogen-induced (44, 49) or type-1 diabetic kidney (17, 18 ) is decreased.
Role of H 2 S in Diabetic Kidney Remodeling and Function
Excess matrix protein synthesis and deposition occur in the diabetic kidney. Recent reports suggest that the H 2 S-producing enzymes and its levels are decreased in diabetes. Upon endogenous induction or exogenous supplementation of H 2 S, matrix remodeling was mitigated, suggesting a correlation between H 2 S deficiency and matrix accumulation. In streptozotocininduced diabetic rats, H 2 S therapy improved renal function, decreased glomerular basement thickening, mesangial expansion, and interstitial fibrosis (49) . In the same study, the authors documented that the reduction of glucose-induced oxidative stress by H 2 S was mediated by activation of the Nrf2 antioxidant pathway that exerts an anti-inflammatory effect by inhibiting NF-B signaling in in vitro podocytes (49) . This finding is in line with our own study on the genetic type-1 diabetic model, where plasma H 2 S levels were low and associated with increased extracellular matrix deposition and reduced vascular compliance which was mitigated by H 2 S treatment (17) .
Previously, our laboratory demonstrated that matrix metalloproteinase-9 (MMP-9) diminishes H 2 S production in the type-1 diabetic (Akita) model and this was, in part, by reducing CBS and CSE enzyme expression (18) . Similar results were also observed in high-glucose treatment in in vitro experiments using glomerular endothelial cells (18) . The regulation of CBS/CSE enzymes by MMP-9 was confirmed using Akita and MMP-9 knockout mice along with partial mitigation of renal remodeling in double knockout (DKO) mice (17) . In addition, we demonstrated that H 2 S therapy improves renal function (17) .
Signaling Cross Talk Between Gaseous Modulators in the Diabetic Kidney
Recently, Lee et al. (20) reported that H 2 S inhibited high glucose-induced protein synthesis in renal epithelial cells (21) . In a separate study, the same group also reported tadalafil, a phosphodiesterase 5 inhibitor, abrogated high glucose-induced global protein synthesis and matrix protein laminin-␥ by increasing the expression and activity of H 2 S-producing enzyme CSE (20) . They also observed that in podocytes, tadalafilinduced AMP-activated protein kinase (AMPK) phosphorylation was mitigated by CSE inhibitor DL-propargylglycine and small interfering RNA against CSE in podocytes (20) . The authors concluded that high-glucose-induced matrix protein synthesis in podocytes involved a complex interaction of the nitric oxide (NO)-H 2 S-AMPK axis (20) . To further define molecular mechanisms of H 2 S signaling in diabetic conditions, we performed in vitro experiments using mouse glomerular endothelial cells. The cells were stimulated with high-glucose and treated without or with a H 2 S donor. Our results suggested that high glucose induced markers of matrix accumulation and autophagy through a LKB1/STRAD/MO25 dependent pathway ( Fig. 1) (16) .
The N-Methyl-D-Aspartate Receptor, H 2 S, and Diabetic Nephropathy
Although H 2 S does not have a specific receptor, it has been reported to modulate the N-methyl-D-aspartate (NMDA) receptor in the brain (13) . The NMDA receptor is a glutamate receptor and ion channel protein mainly found in the nerve cells involved in controlling synaptic plasticity and memory function (22) . In 2002, Deng et al. (6) demonstrated that NMDA receptors were also expressed in the kidney cortex and exerted a tonic vasodilatory response. Inhibition of the receptors caused marked renal vasoconstriction and reduction in renal blood flow in response to glycine infusion (6). However, it was not known whether H 2 S affects the NMDA receptor in the kidney to modulate function. For the first time, our laboratory demonstrated the role of H 2 S in renal NMDA receptormediated remodeling and dysfunction (18) . Our findings suggested that diabetic kidney remodeling was, in part, due to reduced H 2 S production due to MMP-9-mediated inhibition of CBS and CSE enzyme activity. (18) . This was associated with disruption of gap junction proteins, connexin-40 and -43. The above changes were reversed by exogenous H 2 S supplementation (18) . More recently, we demonstrated that an increased renal-resistive index (RI), excess ECM deposition, elevated plasma creatinine, and diminished renal vascular density and cortical blood flow were normalized with H 2 S treatment in Akita kidneys (17) . These findings suggest that H 2 S has the potential to prevent diabetic nephropathy by preserving renal microvascular architecture and function. A possible pathway of H 2 S-dependent renal remodeling and signaling mechanism is shown in Fig. 1 .
Perspective and Concluding Remarks
In summary, studies on H 2 S have revealed a significant role in a variety of physiological and pathophysiological processes. A decrease in H 2 S level has been implicated in several pathologies, including diabetic nephropathy, in animals and humans (11, 47, 49) . In contrast, increased H 2 S levels have been reported to contribute to ␤-cell apoptosis, leading to reduced mass and thus insulin, neutrophil infiltration, and inflammation in lipopolysaccharide-induced endotoxic shock in the lung and liver and synovial inflammation (24, 39, 46) . However, the measurement of H 2 S in some of the earlier studies is inaccurate and overestimated due to the lack of sensitive techniques and partly due to its volatile nature. In addition, studies which showed improvement in pathology used crude H 2 S donors such as sodium hydrogen sulfide (NaHS), which is not suitable for human therapy due to its short-time bioavailability and possible toxicity. Current research is now focused on developing novel H 2 S-releasing compounds, such as GYY4137, AP39, and SG-1002, which are known to simulate the endogenous production of H 2 S in the body. These compounds are safer than bolus doses of NaHS or sodium sulfide (Na2S), which instantly releases H 2 S. Furthermore, the slow-releasing compounds can deliver H 2 S over a longer period of time. In animal models, GYY4137 has been shown to improve vasculopathy (26, 31) . Since supplementation of H 2 S has the potential to prevent and/or improve DN by preserving renal microvasculature and function, additional experiments are needed to test the safety and efficacy using the newer H 2 S-releasing compounds. In early phase I and phase II clinical trials, the novel H 2 S donor SG-1002 significantly increased blood levels of H 2 S and nitrite, suggesting increased nitric oxide availability in healthy and heart failure subjects (32, 33) . To fully exploit the therapeutic potential of H 2 S, larger multicenter cohort studies are required to investigate its beneficial effects not only in the diabetic kidney but also in the other organs affected by diabetes.
Recently, a clinical trial using N-acetyl cysteine (NAC), a derivative of cysteine and substrate for H 2 S, has completed in patients with chronic kidney disease and patients on dialysis (ClinicalTrials.gov Identifier: NCT01232257). The objective of this study was to examine whether NAC treatment would increase plasma H 2 S levels and decrease oxidative stress and inflammation. While the results are awaited, it can be speculated that the outcomes will likely provide us insight into the H 2 S backup mechanism during nitric oxide deficiency in chronic kidney disease patients.
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